Taipei, Taiwan, 11th December 2023: In a momentous event last Friday, Bora Pharmaceuticals hosted the “Bora X SunWay – DAY 1” gathering, officially embracing SunWay Biotech into the Bora Pharmaceuticals family. The event, inaugurated by Mr. Bobby Sheng, Chairman of Bora Pharmaceuticals and newly appointed Chairman of SunWay Biotech, set the stage for a collaborative venture under the banner of “Bora X SunWay,” marking the initiation of a new chapter in international expansion.
Chairman Bobby Sheng emphasized, “SunWay’s exclusive technologies and raw material formulation expertise, accumulated over the years, are truly unparalleled globally. With SunWay’s robust R&D foundation, their technical achievements position them as a leader in the global nutraceutical market. SunWay is a hidden gem in Taiwan, and with the integration of Bora Pharmaceuticals’ global network, we are confident in showcasing SunWay’s expertise and products on the world stage.”
Professor Pan Tzu-ming, Honorary Professor at National Taiwan University and current CTO of SunWay Biotech, highlighted, “Our rigorous scientific methods and dedication have resulted in over 200 publications, bringing beneficial research findings into products that make health easily attainable. Through the strategic alliance with Bora Pharmaceuticals, we look forward to leading SunWay towards internationalization, enabling more individuals worldwide to enjoy the health benefits of our products.”
SunWay Biotech showcases its unique achievements and positions the company as a champion in the nutraceutical sector in Taiwan.
- Notably, SunWay’s collaborated Red Yeast Rice and Probiotic products, hold the leading market share in Taiwan.
- Approved by U.S. FDA for New Dietary Ingredients (NDI)
- Contributed to the creation of the Red Yeast Rice supplement chapter in the U.S. Pharmacopeia (USP)
- Received the “Herbal Product of the Year” award at the 2023 Nutraingredient Asia Awards.
- Sunway’s Red Yeast Rice raw material is globally unique for being free of Monacolin K/Statin and holds the exclusive recognition of three health food green labels in Taiwan.
In September of this year, SunWay Biotech expanded its business reach globally, with its Ankascin 568-R product officially receiving registration certification from the National Food Safety Authority (NFSA) of Egypt. Collaborations with local partners in Egypt are underway, marking SunWay’s entry into the African market!
About Bora Pharmaceuticals:
Bora Pharmaceuticals Co., Ltd. (Stock Code: 6472), established in 2007, stands among Taiwan’s largest pharmaceutical groups and holds the position of the country’s leading pharmaceutical manufacturing company by production capacity. Exporting pharmaceutical products globally in over 100 countries, Bora is dedicated to establishing itself as a worldwide leader in the pharmaceutical industry, consistently providing high-quality, efficient, and reliable services and products to its global customer. Contact us for more information.
About SunWay Biotech:
SunWay Biotech Co., Ltd. (Stock Code: 1271), founded in 2007, specializes in professional research and nutraceutical raw material formulation. In collaboration with Professor Pan Tzu-ming from the Department of Biochemical Science and Technology at National Taiwan University, SunWay focuses on the research, design, and manufacturing of NTU 568 Red Yeast and NTU 101 Lactic Acid Bacteria strains, offering comprehensive custom product development services to its customer.
Press Release Contact:
Angela Luan, Investor Relations Director
Phone: +886-2-2657-3350 #113
Email: angela.luan@bora-corp.com
